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ABSTRACT 
Background Objectives: The risk of adefovir dipivoxil resistance emergence has increased in lamivudine-resistant hepatitis 
B infected patients. The mutations known as causing adefovir resistance, rtN236T and rtA181V/T, are detected within the 
D and B functional domain of the HBV polymerase, respectively. In this study, we intended to determine the pre-existing 
adefovir-resistance mutations in patients infected with LAM resistant mutants prior to starting adefovir therapy.
Material and Methods: The study included 30 patients with chronic hepatitis B with lamivudine resistance mutations in the 
YMDD motif that experienced viral breakthrough. 
Results: After alignment of protein coding sequences, the rtN236T mutation was observed in two (6.6 %) patients, while 
twenty-eight others had neither rtN236T, nor rtA181V/T mutation. All 30 patients were infected with genotype D of 
hepatitis B virus.
Conclusions: The early detection of LAM-resistance mutations may allow a timely chance of therapy to avoid hepatitis flare-
up. This data suggests that monitoring of ADV-resistance mutations in ADV naïve patients can be considered in selecting the 
appropriate anti-viral regimen.
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INTRODUCTION
Chronic Hepatitis B (CHB) remains a major health 
problem world-wide and can lead to hepatocellular 
carcinoma and cirrhosis (1, 2). Several therapeutic 
agents including pegylated interferon and nucleotide/
nucleoside analogues such as lamivudine, adefovir, 
telbivudin, entecavir and tenofovir (3, 4) are 
available.
Lamivudine has been widely used as the first-line 
therapy in patients with chronic hepatitis B with well-
documented efficiency and safety profile (5, 6). Long 
term  usage of  lamivudine leads to development 
of drug resistance which is mainly associated with 
mutations in the YMDD motifs, substitution of 
methionine by either valine (rtM204I) or isoleucine 
(rtM204I) in the tyrosine-methionine-aspartate-
aspartate (YMDD) motif of the HBV polymerase 
C domain (7-9). The rtL180M mutation may occur 
concurrently with YMDD mutations and serves as a 
compensation for better replication fitness (10). The 
risk of emerging LAM resistance is 14-32% in the 
first year and rises up to 70% by the fifth year (6).
Adefovir dipivoxil (ADV) is a nucleotide analogue 
that interferes with the reverse transcriptase activity 
of hepatitis B virus (HBV) polymerase upon viral 
replication. ADV has become an alternative treatment 
for HBV infection regarding the high rate of 
lamivudine resistance during prolonged viral therapy 
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(11). However, viral resistance to ADV has been 
shown after either switching to or adding adefovir to 
previous regimen (ADV add-on therapy) in patients 
with LAM resistance (12,13). The risk of developing 
adefovir resistance was 2% in the first year and 25-
30% by the second and fourth years of mono-therapy 
in treatment-naïve cases respectively (12-14). The 
risk of ADV resistant emergence increased to 20% 
in LAM-resistant patients with switching to ADV 
mono-therapy within 1.5 years of ADV treatment (3). 
The mutations known as causing adefovir resistance, 
rtN236T and rtA181V/T (15, 16), are detected 
within the D and B functional domain of the HBV 
polymerase, respectively (17). 
The aim of the present study was to determine 
the prevalence of the pre-existed ADV-resistance 
mutations in patients infected with LAM resistant 
mutants of HBV prior to starting ADV therapy.
MATeRIALS AND MeTHODS
Thirty chronic hepatitis B patients with the 
documented presence of genotypic resistance 
mutation to lamivudine were identified between 
October 2010 to December 2011. After at least 6 
months lamivudine administration; the emergence 
of YMDD mutations was identified in those patients 
using restriction fragment length polymorphism 
(RFLP) methods (18).
Biochemical tests and viral markers. Laboratory 
tests were performed at baseline and on a monthly 
basis during treatment. Serum ALT levels, HBeAg, 
anti-Hbe and HBsAg were determined using ELISA 
kits (Dia.Pro. Diagnostics, Italy) according to 
manufacturer’s instructions. HBV DNA level in 
serum was measured using COBAS Amplicor (Roche 
Diagnostic, USA), this assay has a detection range 
between 2 × 102-109 copies/ml.
HBV DNA was extracted from 140 μl of serum using 
the QIAamp DNA mini kit (Qiagen Ltd. Germany) 
according to the manufacturer’s instructions. 
Extracted DNA eluted in 100 μl of elution buffer and 
stored at -20ºC until use.
Direct sequencing. To amplify the HBV 
polymerase gene by the nested PCR, we 
employed the primers and PCR program of 
Osiowy et al. (19). Briefly, the primers:  spr1F 
( 5 ´ - G T T C A G G A A C A G TA A G C C C - 3 ´ ) 
and the reverse primer spr1R (5’- 
GAAAGGCCTTGTAAGTTGGCG-3’) were used in 
the first round PCR. The inner primers: sense, spr2F 
(5- GGTGGACTTCTCTCAATTTTCTAGG-3) and 
antisense spr2R (5- ACTTTCCAATCAATAGGCC-3) 
were used for nested PCR. The following PCR 
thermal-cycling program was performed: 35 cycles 
consisting of 94ºC for 30s , 56ºC for 30s (first round) 
or 50ºC for 30s (second round), and 72ºC for 40s. 
The intended fragment were amplified using 2X PCR 
master mix solution (i-tag, iNtRON Biotechnology, 
Inc. Korea) with 5 μl of DNA extract and 2 μl of the 
first round PCR product. After the amplification of 
polymerase gene, the amplicons (730 bp) were visible 
after agarose gel electrophoresis and gel purified 
using High Pure PCR Product purification kit (Roche 
Diagnostic Gmbh). The purified PCR products were 
bi-directionally sequenced commercially (SEQLAB, 
Germany) using inner primers.
To perform the phylogenetic analysis, obtained 
sequence data were used to identify the genotype of 
each sample, using the NCBI genotyping tool (20). 
HBV polymerase encoded protein sequences were 
translated from each sample nucleotide sequences 
using Bioedit software (The BioEdit Sequence 
Alignment Editor software, Department of the 
Microbiology, North California State University) and 
confirmed by visual inspection. Sequences were then 
aligned with HBV polymerase coding sequences from 
the Gene Bank data base using CLUSTAL W program 
(http://www.ebi.ac.uk/Tools/msa/clustalw2).
ReSULTS
Baseline characteristics. Baseline characteristics 
of enrolled patients prior to starting ADV therapy 
are listed in Table 1. All 30 patients were already 
infected with genotype D of hepatitis B virus. All of 
the patients showed viral breakthrough after at least 6 
months of LAM therapy, the mean serum HBV-DNA 
level was 1 × 106.2 copy/ml. HBeAg was positive in 
28 (93%) of cases. The median ALT level was 177 
IU/L (Table 1). LAM resistance analysis using RFLP 
method identified the type of YMDD mutations; 
24(80%) patients had the rtM204I mutation, 2 (6.6%) 
had the rtM204V and 4(13.3 %) had both.
Detection of ADV resistance mutations by direct 
sequencing. After alignment of protein coding 
sequences, the rtN236T mutation was observed in 
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two (6.6%) patients (Fig. 1), while twenty eight others 
had neither rtN236T, nor rtA181V/T mutation (Table 
2.) Genetic distance was estimated using the Kimura 
two-parameter matrix (28) and phylogenetic tree was 
constructed by the neighbor-joining (NJ) method 
(29). Bootstrap resampling and reconstruction were 
carried out 1,000 times to confirm the reliability of 
the phylogenetic tree (Data not shown). 
DISCUSSION
The emergence of resistant mutants to nucleos(t)
ide analogues is the major cause of treatment failure 
in patients with CHB (2). LAM is the most common 
oral antiviral drug for the treatment of CHB. However, 
because of its widespread consumption, an increasing 
number of the emergence of LAM-resistant mutants 
has been reported increasingly. 
Currently, the mostly accepted therapeutic guideline 
to overcome the LAM-resistance problem is ADV add-
on treatment (11). In this study we included patients 
with LAM resistant mutations only before starting 
ADV treatment, because the aim of this study was to 
determine the pre-existing ADV-resistance mutations 
in those patients. A multivariate analysis (including 
adefovir treatment HBV DNA levels, ALT levels, 
HBeAg status) showed the baseline characteristics of 
the included patients.
The results of alignment of protein coding 
sequences indicated the rtN236T mutation was 
observed in two (6.6%) patients, while 28 others 
had neither rtN236T, nor rtA181V/T mutation. 
There have been a number of studies to support 
the correlation between clinical response to antiviral 
agents and the HBV genotype, and yet there are 
still controversial reports (21, 22). It appears that 
genotype A develop LAM resistance more frequently 
or quite rapidly in comparison with genotype D (24). 
However, several reports have shown no association 
between genotype and the emergence of LAM 
resistance (25, 26).  
In 2005, a report indicated an association between 
existence of HBV genotype D and an increased risk 
of ADV resistance (27). In present study since all 
patients were infected with HBV genotype D, the 
incidence of ADV resistance does not reflect true 
association between genotype D and the emergence 
of ADV resistance rate. Thus, a larger study with 
inclusion of other HBV genotypes is necessary to 
deeply understand the relationship.
Recent studies suggest new alternative strategies to 
conquer the rapid and frequent development of drug 
resistant mutant viruses. Newly approved antiviral 
agents which are able to suppress viral replication 
robustly, will probably decrease the likelihood of 
selecting resistance (12, 13).
Pre-existing ADV-resistance mutations such as 
rtN236T, prior to starting ADV mono-therapy or 
ADV add-on treatment may adversely affect its 
antiviral efficacy. Moreover the early detection 
of LAM-resistance mutations may allow a timely 
chance of therapy to avoid hepatitis flares. This 
study suggests that monitoring of ADV-resistance 
mutations in ADV naïve patients can be of a great 
importance.   
Baseline characteristics of patient
No. of patients 30
Age (years), median (range) 38 (20-58)
Gender (M/F) 23/7
HbeAg positivity, n (%) 28 (93%)
ALT (IU/L, median, range) 177 (35-1200)
HBV-DNA (log10 copies/ml), mean±SD 6.3 ± 1.33
 LAM resistance mutation profile (n, %)
rtM204V/I 30 (100%)
rtM204I 24 (80%)
rtM204V 2 (6.6%)
rtM204I+V 4 (13.3%)
Table 1.  Baseline characteristics of patient and lamivudine 
resistance mutation profile. 
Genotype
No. (%) of patients
rt181 rt236 rt181/236
D (0%) 0 (6.6%) 2 (0%) 0
Table 2. Detection of adefovir dipivoxil resistance associated 
mutations within the HBV polymerase.
fig. 1. Alignment of coding sequences for detection of resistance mutations within the HBV polymerase.
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